Rolf stahel biography of abraham

          The combination of cisplatin with Mapatumumab or Lexatumumab synergistically inhibited the cell growth and enhanced apoptotic death.

        1. The combination of cisplatin with Mapatumumab or Lexatumumab synergistically inhibited the cell growth and enhanced apoptotic death.
        2. Rolf A. Stahel, MD, Department of Oncology, University Hospital in Zurich, Switzerland, and current president of ESMO.
        3. Rolf Stahel, chair of the ESMO.
        4. Malignant pleural mesothelioma (MPM) is a generally fatal thoracic neoplasia that arises from the pleural lining.
        5. Rolf xxxxxxxxxx HERMES Foundation Aebischer.

          6. Rolf Stahel, chair of the ESMO.!

          Two Experts Weigh in on Treating Patients With Metastatic NSCLC and EGFR TM Mutations

          Mutations in the epidermal growth factor receptor (EGFR) have served as the basis for using targeted therapies with tyrosine kinase inhibitors (TKIs) in patients with advanced non—small cell lung cancer (NSCLC); however, it is now known that the response duration to EGFR TKIs is short-lived for patients who harbor the exon 20 TM mutation, and TM has been recognized as the most common mechanism of TKI drug resistance.

           Recent research has been aimed at expanding treatment options for patients with TM NSCLC, who are typically treated with cytotoxic chemotherapies. 

          EGFRTM: Some Recent Findings

          • Recent, back-to-back publications in theNew England Journal of Medicinehave demonstrated the clinical activity of two next-generation TKIs, AZD and rociletinib, in patients with TM mutation and disease progression while on first- or second-generation EGFR TKIs.1,2
          • The results of a